MA1-411

antibody from Invitrogen Antibodies

Targeting: PGR NR3C3, PR

Antibody data

Submit

Validation data

Product number: MA1-411 - Provider product page
Provider: Invitrogen Antibodies
Product name: Progesterone Receptor Monoclonal Antibody (Alpha PR6)
Antibody type: Monoclonal
Antigen: Purifed from natural sources
Description: MA1-411 reacts with high affinity to the B form of the progesterone receptor from human, mouse, rat, rabbit, bovine, ovine, chicken, and guinea pig tissues. This antibody does not cross-react with estrogen receptor or glucocorticoid receptor.
Antibody clone number: Alpha PR6
Concentration: 1 mg/mL

PGR protein structure - MA1-411 shown in red.

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Scoring results PRB experiment 1 . Results from manual scoring of PRB immunohistochemistry results in stroma (upper panel), luminal epithelium (LE, middle panel) and myometrium (bottom panel). The ""box-and-whisker plot"" represents the median value with 50% of all data falling within the box. The whiskers extend to the 5th and 95th percentiles. An asterisk indicates a significant (p < 0.05) difference compared to the OvxC group.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Nf1 deficiency induces ER + /PR + mammary tumors. We observed mammary tumors with diverse mammary histology in G0 - G2 animals. a Nf1 females and b Nf1 males developed mammary adenocarcinomas with mixed histology including acinar, cystic, papillary, ductal, and solid features. All images were taken at 100X magnification. c Immunostaining of Nf1 mammary tumors ( rNf1 #6) for estrogen receptor, progesterone receptor, HER2, Ki67, and pan-cytokeratin (AE1/AE3). All immunostaining images were taken at 200X magnification

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Immunohistochemistry experiment 1 . Representative images of immunohistochemical results from each hormone treatment group in experiment 1, PRAB A-H , PRB I-O . Treatment groups are as follows: OvxC: A and I , 24E: B and J . 24P: C and K , 48E: D and L , 48P: E and M , 24E+24P: F and N , 24P+24E: G and O . Magnification bar 30 mum in images A-H and 50 mum in images I-O.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Immunohistochemistry experiment 2 . Representative images of immunohistochemical results from the immature ( A ), cycling ( B,C ) and pregnant rats ( D-H ). Image F shows PRB immunostaining while all the others show PRAB. The arrow in image H indicates the negative cells in the placenta. Magnification bar 30 mum in all images.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Immunohistochemistry experiment 3 . Representative images of immunohistochemical results from the agonist treated rats, PRAB in left columnand PRB in right column. Representative images are shown from a rat in each treatment group as follows: OvxC ( A,B ), E2 ( C,D ), PPT ( E,F ) and DPN ( G,H ). The insert shows the myometrium from the same uterus. Magnification bar 30 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Immunohistochemical localization of PR and PRB in the superficial endometrial stroma (Str), glands (G) and luminal epithelium (Le). Positive nuclear immunostaining for PR is present in the study groups as shown: OVX ( a ); CEE ( c ); MPA ( e ); CEE /MPA ( g ), and TAM ( i ). Nuclear PRB immunostaining is shown for: OVX ( b ); CEE ( d ); MPA ( f ); CEE /MPA ( h ) and TAM ( j ) groups, (bar = 30 mum). A negative control is shown for PR where the first antibody is replaced by mouse IgG ( k ). Positive controls for PRB immunostaining in human endometrium ( l ) and breast tissue from a CEE treated monkey ( m ), (bar = 30 mum).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Image analysis scores of positive PR immunoreactivity in superficial stroma ( a ), superficial glands ( b ) and luminal epithelium ( c ). PRB immunostaining is shown in superficial stroma ( d ), superficial glands ( e ) and luminal epithelium ( f ). Box and whisker plots representing the median value with 50% of all data falling within the box. The whiskers extend to the 5 th and 95 th percentiles. In OVX, MPA and CEE/MPA groups: n = 5, in CEE group n = 4 and in the TAM group n = 6. Values with different letter designations are significantly different (p < 0.05). Values with * is significantly different (p < 0.05) to OVX control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 5 Composition and distribution of the fetal and maternal macrophage population in bovine placenta. Placental sections of a healthy term cow were stained with LAMP-1 (red), alpha-SMA (green, cytoplasm) and PGR (green, nucleus). MS: maternal stroma and FV: fetal villi. Scale bar =50mum

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 4 Immunofluorescent labeling of cell populations located in maternal stroma. Placental sections from healthy term cows were stained with LAMP-1 (red), alpha-SMA (green, cytoplasm) and PGR (green, nucleus). The detection of PGR was performed to more easily differentiate cell types in maternal stroma. In the merged images maternal macrophages (arrowheads) and myofibroblasts (arrows) in maternal stroma (MS) adjacent to fetal villi (FV) are labelled. Nuclei were labeled with DAPI (blue). Scale bar = 15 mum

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 Localization of endometrial PGR. PGR staining was most abundant in endometrial luminal epithelium (LE) and superficial glandular epithelia (sGE) in CO-treated ewes necropsied on day 9 of pregnancy and was markedly reduced in endometria of P4-treated ewes necropsied on day 9 and 12 ( a and b ). Similar PGR localization and staining intensity was found in the LE of CO and P4-treated ewes necropsied on day 12. PGR in endometria of P4-treated ewes necropsied on day 12 was least abundant in both sGE and LE. Scale bar represents 100 mum. Only endometria from ewes which were considered pregnant with normally developed conceptuse were utilized for these analyses